Over a hundred lawsuits have been filed against Janssen Pharmaceuticals, alleging that the pharmaceutical giant failed to warn consumers that its drug Elmiron could cause permanent eye damage.
Predicting there could be several hundred more lawsuits against Janssen Pharmaceuticals, the U.S. Judicial Panel on Multidistrict Litigation issued an order on December 15, 2020, to create a multidistrict litigation (MDL) for the federal cases.
An MDL is a legal procedure that consolidates multiple federal cases into one case, tried under one court, in order to speed the process of handling these complex cases. The MDL order consolidated the nearly 130 existing Elmiron lawsuits, transferring them to the District of New Jersey to be tried.
Contact us to receive a free case evaluation form and learn if you could be eligible to participate in an Elmiron lawsuit.
What Is Elmiron?
Elmiron (pentosan polysulfate sodium) is a drug that treats bladder conditions. It works by protecting the bladder from harmful and irritating substances in urine. The drug is most commonly prescribed to treat interstitial cystitis (IC), a chronic inflammatory condition that impacts an estimated one million patients in the U.S.
Read more about Elmiron Usage & Dosage Drug Information.
The Allegations Against Elmiron
Although Elmiron is prescribed to treat bladder conditions, some allege that extended use of the drug could cause serious vision and eye issues. Between the drug’s release in 1996 through to this year, hundreds of reports were filed to the U.S. Food and Drug Administration (FDA) claiming adverse events such as vision loss and other eye conditions. It wasn’t until June 2020 that Elmiron’s safety label was updated to warn patients that the drug could cause retinal damage.
Between this update and the drug’s initial release, over a hundred lawsuits were filed against Janssen Pharmaceuticals alleging the drug caused an eye condition called maculopathy. Maculopathy is an eye disease that can lead to vision loss due to damage to a part of the retina called the macula. The macula is an important part of the retina that allows us to focus our central vision.
Scientific research is only further substantiating the claims of plaintiffs alleging eye damage after taking Elmiron. A study by the American Academy of Ophthalmology published in October 2019 found that a quarter of patients with significant exposure to the drug Elmiron showed signs of retinal damage. The study also reports that Elmiron appears to be “toxic to the retina.”
Symptoms of Elmiron-Related Maculopathy
Patients who alleged they have developed maculopathy due to long-term use of Elmiron reported symptoms including blurred vision, vision loss, loss of night vision, difficulty reading, and blinds spots in their central vision.
If you have taken Elmiron and are experiencing any of the above symptoms, visit your eye doctor for an exam right away to see if any of your vision problems could be linked to the drug.
Have You Experienced Eye Problems After Using Elmiron?
If you were diagnosed with vision loss or eye disease after taking Elmiron for more than two years, you may be eligible for a lawsuit against Janssen. Contact us for a FREE CASE EVALUTION or read on to learn if you qualify for an Elmiron lawsuit and what you could recover if you are eligible to participate in a lawsuit.